CG Oncology, Inc. SEC Filings

CG Oncology, Inc. filed its Q3 2025 report, showing total revenues of $1.666 million and a net loss of $43.808 million for the quarter. Operating costs were driven by research and development $27.884 million and general and administrative $23.334 million, offset by interest income $7.321 million.

Liquidity remains strong with approximately $680.3 million of cash, cash equivalents and marketable securities and working capital ~$665.3 million as of September 30, 2025. Under its at‑the‑market program, the company sold 1,515,151 shares at $33.00 for net proceeds $48.7 million in Q3, and subsequently sold 2,343,967 shares for net proceeds $98.4 million after quarter‑end.

CG Oncology consolidated Biovire following a July 2025 conversion event, recognizing $12.805 million of goodwill and $1.700 million in intangible assets; the total consideration was $26.844 million. The company reported positive clinical updates for cretostimogene, including a 24‑month complete response rate of 41.8% (46/110) in BOND‑003 Cohort C and initiated its BLA submission in Q4 2025. In litigation, a jury verdict favored the company regarding ANI’s claims, with no damages and no 5% royalty owed.

CG Oncology (CGON) furnished an update on its financial results under Item 2.02. The company announced it issued a press release covering results for the quarter ended September 30, 2025, which is attached as Exhibit 99.1.

The company states the information in this report, including Exhibit 99.1, is being furnished and not filed pursuant to General Instruction B.2. The filing also lists the company’s common stock on The Nasdaq Global Select Market under the symbol CGON.

CG Oncology (CGON): Form 4 insider activity — A director reported transactions on 10/13/2025. The reporting person exercised 1,000 stock options at $0.60 (Code M) and sold 1,000 shares at $43.25 (Code S).

The sale was effected under a Rule 10b5-1 trading plan adopted on September 6, 2024. Following these transactions, the reporting person held 0 shares of common stock directly and 118,077 derivative securities (director stock options) directly.

Director James J. Mulay completed option-related transactions on 10/09/2025. He exercised 5,903 stock options at an exercise price of $3.72 per share, then sold the resulting 5,903 shares at $43.99 per share pursuant to a Rule 10b5-1 trading plan adopted on 06/06/2025. After these transactions the reporting person beneficially owns 0 shares of common stock and retains derivative exposure showing 1,962 derivative securities reported as beneficially owned following the transactions. The reported stock option vests in 36 monthly installments beginning on 07/14/2023 and has an expiration date of 06/13/2033. The Form 4 was signed on 10/10/2025 by an attorney-in-fact.

Notice of Proposed Sale under Rule 144: An insider-related Form 144 for the issuer indicates a proposed sale of 6,557 common shares, valued at approximately $266,935.47, to be sold on 10/09/2025 on NASDAQ. The securities were acquired the same day via exercise of stock options and paid in cash. The filing also discloses multiple recent Rule 10b5-1 plan sales by the same account: 12,755 shares on 09/29/2025 for $499,886.31, 3,574 shares on 09/19/2025 for $139,350.26, 19,112 shares on 09/18/2025 for $745,627.92, and 27,015 shares on 09/05/2025 for $851,759.01. The filer certifies no undisclosed material adverse information and includes the standard attestation regarding Rule 10b5-1 trading plans.

Leonard E. Post, a director of CG Oncology, Inc. (CGON), reported transactions dated 09/30/2025. The filing shows a purchase/acquisition of 5,000 common shares and a simultaneous sale/disposition of 5,000 common shares sold under a Rule 10b5-1 trading plan at a weighted average price of $40.09. The reporter holds a fully vested director stock option with an exercise price of $0.60 covering 5,000 shares and reports total beneficial ownership of 119,077 shares following the transactions. The sale was effected under a 10b5-1 plan adopted on 09/06/2024.

Insider transactions by CG Oncology (CGON) director James J. Mulay on 09/29/2025: Mr. Mulay exercised 12,755 fully vested director stock options at an exercise price of $1.82 per share, converting them into 12,755 shares of common stock. On the same date those 12,755 shares were sold under a Rule 10b5-1 trading plan at a weighted average price of $39.19 per share (individual sale prices ranged from $38.99 to $39.41). Following the reported transactions, the reporting person holds no common shares but retains the director stock option record showing 12,755 underlying shares with an exercise price of $1.82 and an expiration of 07/18/2031. The Form 4 was signed by an attorney-in-fact.

CG Oncology, Inc. filing a Form 144 notifies the proposed sale of 5,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $195,400, to be sold on 09/30/2025 on NASDAQ. The shares were acquired the same day by exercise of stock options and paid in cash. The filer reports prior Rule 10b5-1 sales by Leonard E. Post totaling 4,000 shares in the past three months (2,000 sold on 07/17/2025 for $56,000; 1,000 on 09/03/2025 for $28,000; 1,000 on 09/15/2025 for $35,100). The filing shows 76,247,581 shares outstanding, so the proposed sale represents a de minimis fraction of outstanding shares.

James J. Mulay, a director of CG Oncology, Inc. (CGON), reported option exercises and immediate sales on September 18-19, 2025. On 09/18/2025 he exercised Director Stock Options to acquire 19,112 shares at an exercise price of $1.82 per share and, pursuant to a Rule 10b5-1 trading plan adopted June 6, 2025, sold those 19,112 shares at a weighted average price of $39.01. On 09/19/2025 he exercised an additional 3,574 options at $1.82 and sold those 3,574 shares at $38.99. The filing states the options were fully vested and the sales reduced the reported non-derivative beneficial ownership to zero following the transactions. The form is signed by an attorney-in-fact on behalf of Mr. Mulay.